Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Human umbilical cord mesenchymal stem cell-derived exosomes (hUC-MSC-Exos) are nano-sized extracellular vesicles secreted by mesenchymal stem cells (MSCs) harvested from the umbilical cord. Developed by The First Affiliated Hospital of Xiamen University, these exosomes are being investigated as a cell-free therapeutic approach for inflammatory ocular surface diseases, including dry eye disease associated with Sjögren's syndrome and chronic graft-versus-host disease (cGvHD). The therapeutic mechanism involves the delivery of bioactive cargo—including microRNAs, proteins, and lipids—that modulate the immune response, inhibit the activation of pro-inflammatory Th17 cells, promote the expansion of regulatory T-cells (Tregs), and reduce the levels of inflammatory cytokines such as TNF-alpha and IL-6. By suppressing ocular surface inflammation and promoting corneal epithelial repair, hUC-MSC-Exos aim to alleviate the symptoms and underlying pathology of severe dry eye.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on human umbilical cord mesenchymal stem cell-derived exosome.